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Background
Amyloidosis is caused by the accumulation of misfolded
proteins, resulting in dysfunction of vital organs (eg,
heart, kidneys, nervous system). Diagnosis and access to
appropriate therapy pose significant challenges, and
there is a paucity of literature depicting the patient (pt)
experience. We conducted a survey to identify the chal-
lenges in establishing a diagnosis of amyloidosis and to
gain insight into the pt experience.
Methods
Pts with any type of systemic amyloidosis and their family
members and caregivers were invited to participate in an
anonymous online survey through email and social media
channels of the Amyloidosis Foundation and an amyloido-
sis awareness group on Facebook. Caregivers and family
members could answer on behalf of pts. The 16-question
survey was developed by the authors and was available to
participants online from January 29 to February 5, 2015.
Here we present survey results focusing on pts with her-
editary and senile systemic amyloidosis (SSA).
Results
In total, 533 persons completed the survey (pts, 58%;
family members, 34%; caregivers, 8%). Overall, most pts
were female (62%) and between 50 and 69 years of age
(62%) (average age at diagnosis, 57 years). Most pts (72%)
had light chain (AL) amyloidosis. Hereditary forms of
amyloidosis included transthyretin (TTR)-related amyloi-
dosis (ATTR; n=37) and hereditary non-TTR amyloidosis
(n=18); SSA/wild-type ATTR was reported by 13 patients.
57%, 33%, and 77% of pts with ATTR, non-TTR, and
wild-type ATTR were male, and average age at diagnosis
was 54, 55, and 71 years, respectively. The most frequently
involved organs were heart and nervous system in pts with
ATTR, kidney and nervous system in pts with non-TTR,
and heart in pts with wild-type ATTR. In pts with ATTR,
non-TTR, and wild-type ATTR, the correct diagnosis was
made within 6 months in 35%, 22%, and 46% of pts,
respectively. For pts with ATTR, the correct diagnosis was
most commonly made by a cardiologist (24%), neurologist
(22%), or primary care physician (11%). For those with
non-TTR, the correct diagnosis was most commonly
made by a hematologist (22%), nephrologist (17%), or spe-
cialist at an amyloidosis center (17%). Pts with wild-type
ATTR most commonly received the diagnosis from cardi-
ologists (62%). Across groups, less than one-third of pts
knew how to enroll in a clinical trial, but half would con-
sider participating if more informed.
Conclusions
A correct diagnosis of hereditary or wild-type ATTR amy-
loidosis often requires numerous physician visits to differ-
ent medical specialists and often occurs when disease is
advanced. Responses obtained in this survey highlight the
challenges experienced by pts with these rare diseases.
These data may identify opportunities to educate pts and
physicians in order to expedite diagnosis, facilitate appro-
priate disease management and access to clinical trials,
and ultimately improve pt survival.
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